Virtual Library

Start Your Search

Ke-Cheng Chen



Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-36 - Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy (ID 11170)

      16:45 - 18:00  |  Author(s): Ke-Cheng Chen

      • Abstract
      • Slides

      Background

      Advanced stage non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor (EGFR) mutation have benefit form treatment with tyrosine kinase inhibitors (TKI). However, the role of multidisciplinary management including neoadjuvant TKI therapy and thoracic surgery is uncertain in advanced stage NSCLC. This retrospective study assessed the impact of the multidisciplinary management in advanced stage EGFR mutation positive NSCLC patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Advanced stage NSCLC patients were retrospectively identified at Department of Surgery, National Taiwan University Hospital from 2006 to 2013 and prospectively observed. Patients with stage IIIA N2 (unresectable), IIIB, and IV EGFR mutation positive NSCLC treated with neoadjuvant TKI without tumor progression followed by thoracic surgery (NT group) were evaluated. Patients with stage IIIA N2 NSCLC treated with cisplatin-based neoadjuvant chemotherapy without tumor progression followed by thoracic surgery (NC group) were also evaluated. Progression-free survival (PFS) and overall survival (OS) were analyzed.

      4c3880bb027f159e801041b1021e88e8 Result

      figure.jpeg

      There were total 88 NSCLC patients in this study. There were 41 men and 47 women. The median age was 58 years. 66 patients were the NC group and 22 patients were the NT group. 60 patients and 20 patients were adenocarcinoma in the NC group and the NT group, respectively. Other patients were squamous cell carcinoma. In the NT group, EGFR status was identified before receiving neoadjuvant TKI therapy. Twelve patients (54.5%) were exon 19 deletion and ten patients were exon 21 L858R mutation. PFS was not significantly different between NC group and NT group (p = 0.645). OS was significantly longer in the NT group than in the NC group (p = 0.028). Exon 19 deletion of the NT group patients had significantly longer OS than the NC group (p = 0.014).

      8eea62084ca7e541d918e823422bd82e Conclusion

      The multidisciplinary management including neoadjuvant TKI therapy and thoracic surgery may possibly have benefit in selected advanced stage NSCLC patients haboring exon 19 deletion.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.